Skip to main content

Advertisement

SpringerLink
Log in

Pancreatectomy After Neoadjuvant FOLFIRINOX Chemotherapy: Identifying Factors Predicting Long-Term Survival

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

A Correction to this article was published on 07 July 2023

This article has been updated

Abstract

Introduction

We aimed to evaluate the long-term outcomes of the association of neoadjuvant chemotherapy with pancreatectomy with vascular resection in patients with locally advanced pancreatic cancer.

Methods

Clinical data from patients who underwent pancreatic resection after neoadjuvant FOLFIRINOX were retrospectively reviewed. Cox analyses were used to identify factors prognostic of overall survival (OS).

Results

FOLFIRINOX protocol was administered pre-operatively with a median number of nine cycles (range 2–18) in 98 patients. Types of resections included pancreaticoduodenectomy (n = 53), total pancreatectomy (n = 17), and distal spleno-pancreatectomy (n = 28). Venous resection and arterial resections were performed in 85 (86.7%) and 64 patients (65.3%), respectively. The overall 90-day mortality and morbidity rates were 6.1% (n = 6) and 47% (n = 47), respectively. The median OS was 31.08 months after surgery. OS rates at one, three, five, and 10 years were 82%, 47%, 28%, and 21%, respectively. According to the type of vascular resection, median OS and 5-year survival rates were exclusive venous resection (31.08 months; 23%) and arterial resections (24.7 months; 27%). Multivariate Cox analysis found lymph node involvement, venous invasion, and total pancreatectomy as independent prognostic factors for OS. According to the presence of 0 or 1–3 risk factors, 5-year survival (85% vs 16%) and median overall survival rates (not reached versus 24.7 months, respectively) were statistically significantly different (p < 0.0001).

Conclusions

A multimodal treatment, including neoadjuvant FOLFIRINOX combined with pancreatectomy with venous and arterial resection, achieves long term survival rates in patients with locally advanced disease. Surgery, in experienced centers, should be integrated into the treatment of patients with locally advanced pancreatic adenocarcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

References

  1. Hackert T (2018) Surgery for pancreatic cancer after neoadjuvant treatment. Ann Gastroenterol Surg 2:413–418

    Article  PubMed  PubMed Central  Google Scholar 

  2. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825

    Article  CAS  PubMed  Google Scholar 

  3. Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261(1):12–17

    Article  PubMed  Google Scholar 

  4. Hackert T, Sachsenmaier M, Hinz U et al (2016) Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg 264(3):457–463

    Article  PubMed  Google Scholar 

  5. Pietrasz D, Marthey L, Wagner M et al (2015) Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEO-FRENCH, prospective. Multicentric Cohort Ann Surg Oncol 22(Suppl 3):S1196-1205

    Article  PubMed  Google Scholar 

  6. Pietrasz D, Turrini O, Vendrely V et al (2019) How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? an AGEO-FRENCH multicentric cohort. Ann Surg Oncol 26(1):109–117

    Article  PubMed  Google Scholar 

  7. Barenboim A, Lahat G, Geva R et al (2018) Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol 44(10):1619–1623

    Article  PubMed  Google Scholar 

  8. Schmocker RK, Wright MJ, Ding D et al (2021) An aggressive approach to locally confined pancreatic cancer: defining surgical and oncologic outcomes unique to pancreatectomy with celiac axis resection (DP-CAR). Ann Surg Oncol 28(6):3125–3134

    Article  PubMed  Google Scholar 

  9. Gemenetzis G, Groot VP, Blair AB et al (2019) Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 270(2):340–347

    Article  PubMed  Google Scholar 

  10. Hashemi-Sadraei N, Gbolahan OB, Salfity H et al (2018) Clinical characteristics of patients experiencing pathologic complete response following neoadjuvant therapy for borderline resectable/locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 41(10):982–985

    Article  PubMed  Google Scholar 

  11. Bachellier P, Addeo P, Faitot F et al (2020) Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes?: a single institution’s experience with 118 patients. Ann Surg 271(5):932–940

    Article  PubMed  Google Scholar 

  12. Mollberg N, Rahbari NN, Koch M et al (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 254(6):882–893

    Article  PubMed  Google Scholar 

  13. Rebelo A, Budeyri I, Heckler M et al (2020) Systematic review and meta-analysis of contemporary pancreas surgery with arterial resection. Langenbecks Arch Surg 405(7):903–919

    Article  PubMed  PubMed Central  Google Scholar 

  14. Del Chiaro M, Rangelova E, Halimi A et al (2019) Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. HPB 21(2):219–225

    Article  PubMed  Google Scholar 

  15. Glebova NO, Hicks CW, Tosoian JJ et al (2016) Outcomes of arterial resection during pancreatectomy for tumor. J Vasc Surg 63(3):722–729

    Article  PubMed  Google Scholar 

  16. Loos M, Kester T, Klaiber U et al (2020) Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg

  17. Napoli N, Kauffmann E, Cacace C et al (2021) Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. Updates Surg 73(1):233–249

    Article  PubMed  Google Scholar 

  18. Truty MJ, Colglazier JJ, Mendes BC et al (2020) En bloc celiac axis resection for pancreatic cancer: classification of anatomical variants based on tumor extent. J Am Coll Surg 231(1):8–29

    Article  PubMed  Google Scholar 

  19. Garnier J, Robin F, Ewald J et al (2021) Pancreatectomy with vascular resection after neoadjuvant FOLFIRINOX: who survives more than a year after surgery? Ann Surg Oncol 28(8):4625–4634

    Article  PubMed  Google Scholar 

  20. Truty MJ, Kendrick ML, Nagorney DM et al (2021) Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg 273(2):341–349

    Article  PubMed  Google Scholar 

  21. Klaiber U, Schnaidt ES, Hinz U et al (2021) Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer. Ann Surg 273(1):154–162

    Article  PubMed  Google Scholar 

  22. Macedo FI, Ryon E, Maithel SK et al (2019) Survival outcomes associated with clinical and pathological response following neoadjuvant folfirinox or gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic cancer. Ann Surg 270(3):400–413

    Article  PubMed  Google Scholar 

  23. Rangelova E, Wefer A, Persson S et al (2021) Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg 273(3):579–586

    Article  PubMed  Google Scholar 

  24. Addeo P, Bachellier P (2021) Pancreaticoduodenectomy with segmental venous resection: a standardized technique avoiding graft interposition. J Gastrointest Surg 25:1925–1931

    Article  PubMed  Google Scholar 

  25. Addeo P, Fattori A, Grunder C et al (2021) Prognostic significance of residual lymphovascular invasion after resection of locally advanced and borderline resectable pancreatic adenocarcinomas treated by neoadjuvant chemotherapy. HPB 23(8):1285–1295

    Article  PubMed  Google Scholar 

  26. Addeo P, Velten M, Averous G et al (2017) Prognostic value of venous invasion in resected T3 pancreatic adenocarcinoma: depth of invasion matters. Surgery 162(2):264–274

    Article  PubMed  Google Scholar 

  27. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bassi C, Marchegiani G, Dervenis C et al (2017) The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years After. Surgery 161(3):584–591

    Article  PubMed  Google Scholar 

  29. Wente MN, Bassi C, Dervenis C et al (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the international study group of pancreatic surgery (ISGPS). Surgery 142(5):761–768

    Article  PubMed  Google Scholar 

  30. Wente MN, Veit JA, Bassi C et al (2007) Postpancreatectomy hemorrhage (PPH): an international study group of pancreatic surgery (isgps) definition. Surgery 142(1):20–25

    Article  PubMed  Google Scholar 

  31. Delpero JR, Bachellier P, Regenet N et al (2014) Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB 16(1):20–33

    Article  PubMed  Google Scholar 

  32. Garnier J, Ewald J, Marchese U et al (2020) Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. BMC Cancer 20(1):203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Fortner JG (1981) Surgical principles for pancreatic cancer: regional total and subtotal pancreatectomy. Cancer 47(6 Suppl):1712–1718

    Article  CAS  PubMed  Google Scholar 

  34. Mihaljevic AL, Hackert T, Loos M et al (2021) Not all Whipple procedures are equal: proposal for a classification of pancreatoduodenectomies. Surgery 169(6):1456–1462

    Article  PubMed  Google Scholar 

  35. Roch AM, House MG, Cioffi J et al (2016) Significance of portal vein invasion and extent of invasion in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. J Gastrointest Surg 20(3):479–487

    Article  PubMed  Google Scholar 

  36. Hartwig W, Gluth A, Hinz U et al (2015) Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. Ann Surg 261(3):537–546

    Article  PubMed  Google Scholar 

  37. Del Chiaro M, Rangelova E, Segersvard R et al (2016) Are there still indications for total pancreatectomy? Updates Surg 68(3):257–263

    Article  PubMed  PubMed Central  Google Scholar 

  38. van Roessel S, van Veldhuisen E, Klompmaker S et al (2020) Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment. JAMA Oncol 6(11):1733–1740

    Article  PubMed  Google Scholar 

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives, Hépatiques Et de La Transplantation, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, France 1, Avenue Moliere, 67098, Strasbourg, France

    Pietro Addeo, Pierre de Mathelin, François Faitot, Caterina Cusumano, Chloe Paul & Philippe Bachellier

  2. Department of Pathology, University of Strasbourg, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France

    Gerlinde Averous

  3. Department of Oncology, University of Strasbourg, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France

    Patrick Dufour

Authors
  1. Pietro Addeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerlinde Averous
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre de Mathelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. François Faitot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Caterina Cusumano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chloe Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patrick Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Philippe Bachellier
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Substantial contributions to the conception or design of the work: All.

Acquisition, analysis, or interpretation of data for the work: All.

Drafting the work or revising it critically for important intellectual content: All.

Final approval of the version to be published: All.

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work is appropriately investigated and resolved: All.

Corresponding author

Correspondence to Pietro Addeo.

Ethics declarations

Conflicts of interest

The authors have no conflict of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised: Reference 1 was corrected.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Addeo, P., Averous, G., de Mathelin, P. et al. Pancreatectomy After Neoadjuvant FOLFIRINOX Chemotherapy: Identifying Factors Predicting Long-Term Survival. World J Surg 47, 1253–1262 (2023). https://doi.org/10.1007/s00268-023-06910-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-023-06910-z

Search

Navigation